Latest filings (excl ownership)
SEC STAFF ACTION
SEC staff action: Order
12 Jun 23
NT 10-Q
Notice of late quarterly filing
14 Nov 22
25-NSE
Exchange delisting
14 Sep 22
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
7 Sep 22
8-K
Termination of a Material Definitive Agreement
2 Sep 22
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
24 Aug 22
10-Q
2022 Q2
Quarterly report
15 Aug 22
8-K
Other Events
11 Aug 22
8-K
Submission of Matters to a Vote of Security Holders
4 Aug 22
DEFA14A
Additional proxy soliciting materials
13 Jul 22
8-K
Allena Pharmaceuticals Announces New Meeting Date and New Record Date for Special Meeting to Approve Reverse Stock Split
12 Jul 22
DEFA14A
Additional proxy soliciting materials
12 Jul 22
8-K
Entry into a Material Definitive Agreement
11 Jul 22
424B5
Prospectus supplement for primary offering
11 Jul 22
8-K
Results of Operations and Financial Condition
8 Jul 22
DEFA14A
Additional proxy soliciting materials
5 Jul 22
8-K
Allena Pharmaceuticals Announces Rescheduling of Special Meeting
5 Jul 22
8-K
Termination of a Material Definitive Agreement
28 Jun 22
S-1
IPO registration
23 Jun 22
8-K
Termination of a Material Definitive Agreement
22 Jun 22
DEFA14A
Additional proxy soliciting materials
24 May 22
DEF 14A
Definitive proxy
24 May 22
D
$4.05M in options, sold $4.05M, 5 investors
17 May 22
10-Q
2022 Q1
Quarterly report
16 May 22
PRE 14A
Preliminary proxy
13 May 22
DEFA14A
Additional proxy soliciting materials
4 May 22
8-K
Allena Pharmaceuticals Announces $2.8 Million Registered Direct Offering
4 May 22
424B5
Prospectus supplement for primary offering
4 May 22
10-K/A
2021 FY
Annual report (amended)
29 Apr 22
10-K
2021 FY
Annual report
31 Mar 22
8-K
Other Events
18 Mar 22
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
25 Feb 22
8-K
Departure of Directors or Certain Officers
2 Feb 22
8-K
Allena Pharmaceuticals Provides Clinical and Corporate Update
4 Jan 22
8-K
Entry into a Material Definitive Agreement
23 Dec 21
424B5
Prospectus supplement for primary offering
23 Dec 21
424B5
Prospectus supplement for primary offering
23 Dec 21
UPLOAD
Letter from SEC
19 Nov 21
Latest ownership filings
SC 13G/A
Third Rock Ventures II, L.P.
14 Feb 23
SC 13G/A
Point72 Asset Management, L.P.
14 Feb 22
4
Richard D Katz
2 Feb 22
4
LOUIS MD BRENNER
2 Feb 22
SC 13G/A
Frazier Healthcare VI, L.P.
28 Jan 22
SC 13G/A
HIRSCHMAN ORIN
25 Jan 22
4
LOUIS MD BRENNER
17 Nov 21
4
Alexey L Margolin
4 Jun 21
4
Robert Alexander
4 Jun 21
4
Allene M. Diaz
4 Jun 21
4
GINO SANTINI
4 Jun 21
4
Ann Calby Miller
4 Jun 21
4
LOUIS MD BRENNER
12 May 21
4
Mark J. Fitzpatrick
8 Apr 21
3
Mark J. Fitzpatrick
8 Apr 21
4
LOUIS MD BRENNER
17 Feb 21
SC 13G/A
Deer VII & Co. Ltd.
16 Feb 21
SC 13G/A
FMR LLC
8 Feb 21
4
Richard D Katz
2 Feb 21
3
Richard D Katz
2 Feb 21
SC 13G
HIRSCHMAN ORIN
25 Jan 21
SC 13G
Empery Asset Management, LP
13 Jan 21
SC 13G/A
SABBY MANAGEMENT, LLC
6 Jan 21
4
EDWARD WHOLIHAN
18 Dec 20
4
LOUIS MD BRENNER
18 Dec 20
SC 13G
Point72 Asset Management, L.P.
10 Dec 20
4
LOUIS MD BRENNER
10 Dec 20
4
James N Topper
18 Nov 20
4
GINO SANTINI
18 Nov 20
4
Alexey L Margolin
18 Nov 20
4
Andrew A. F. Hack
18 Nov 20
4
Allene M. Diaz
18 Nov 20
4
Robert Alexander
18 Nov 20
4
Ann Calby Miller
6 Oct 20
3
Ann Calby Miller
6 Oct 20
SC 13G
Empery Asset Management, LP
9 Jun 20
SC 13G
SABBY MANAGEMENT, LLC
3 Jun 20
4
LOUIS MD BRENNER
29 May 20
4
EDWARD WHOLIHAN
29 May 20
SC 13G/A
MORGAN STANLEY
7 May 20